Combination therapy is superior to sequential monotherapy for the initial treatment of hypertension: a double-blind randomized controlled trial

MacDonald, T. M. et al. (2017) Combination therapy is superior to sequential monotherapy for the initial treatment of hypertension: a double-blind randomized controlled trial. Journal of the American Heart Association, 6(11), e006986. (doi: 10.1161/JAHA.117.006986) (PMID:29151036) (PMCID:PMC5721778)

[img]
Preview
Text
151962.pdf - Published Version
Available under License Creative Commons Attribution.

1MB

Abstract

Background: Guidelines for hypertension vary in their preference for initial combination therapy or initial monotherapy, stratified by patient profile; therefore, we compared the efficacy and tolerability of these approaches. Methods and Results: We performed a 1‐year, double‐blind, randomized controlled trial in 605 untreated patients aged 18 to 79 years with systolic blood pressure (BP) ≥150 mm Hg or diastolic BP ≥95 mm Hg. In phase 1 (weeks 0–16), patients were randomly assigned to initial monotherapy (losartan 50–100 mg or hydrochlorothiazide 12.5–25 mg crossing over at 8 weeks), or initial combination (losartan 50–100 mg plus hydrochlorothiazide 12.5–25 mg). In phase 2 (weeks 17–32), all patients received losartan 100 mg and hydrochlorothiazide 12.5 to 25 mg. In phase 3 (weeks 33–52), amlodipine with or without doxazosin could be added to achieve target BP. Hierarchical primary outcomes were the difference from baseline in home systolic BP, averaged over phases 1 and 2 and, if significant, at 32 weeks. Secondary outcomes included adverse events, and difference in home systolic BP responses between tertiles of plasma renin. Home systolic BP after initial monotherapy fell 4.9 mm Hg (range: 3.7–6.0 mm Hg) less over 32 weeks (P<0.001) than after initial combination but caught up at 32 weeks (difference 1.2 mm Hg [range: −0.4 to 2.8 mm Hg], P=0.13). In phase 1, home systolic BP response to each monotherapy differed substantially between renin tertiles, whereas response to combination therapy was uniform and at least 5 mm Hg more than to monotherapy. There were no differences in withdrawals due to adverse events. Conclusions: Initial combination therapy can be recommended for patients with BP >150/95 mm Hg. Clinical Trial Registration URL: http://www.ClinicalTrials.gov. Unique identifier: NCT00994617.

Item Type:Articles
Additional Information:The study was funded by a special project grant from the British Heart Foundation (number SP/08/002). Further funding was provided by National Institute of Health Research Comprehensive Local Research Networks. Williams, Sever, Caulfield and Brown are National Institute of Health Research Senior Investigators. Williams is supported by the National Institute of Health Research University College London Hospitals Biomedical Research Centre. Caulfield is supported by the National Institute of Health Research Cardiovascular Biomedical Research Unit at St Bartholomew’s Hospital, London. McCann is supported by National Institute of Health Research Research Fellowship.
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:McInnes, Professor Gordon and Ford, Professor Ian and Padmanabhan, Professor Sandosh
Authors: MacDonald, T. M., Williams, B., Webb, D. J., Morant, S., Caulfield, M., Cruickshank, J. K., Ford, I., Sever, P., Mackenzie, I. S., Padmanabhan, S., McCann, G. P., Salsbury, J., McInnes, G., and Brown, M. J.
Subjects:R Medicine > R Medicine (General)
College/School:College of Medical Veterinary and Life Sciences > Institute of Cardiovascular and Medical Sciences
College of Medical Veterinary and Life Sciences > Institute of Health and Wellbeing > Robertson Centre
Journal Name:Journal of the American Heart Association
Publisher:American Heart Association
ISSN:2047-9980
ISSN (Online):2047-9980
Published Online:18 November 2017
Copyright Holders:Copyright © 2017 The Authors
First Published:First published in Journal of the American Heart Association 6(11): e006986
Publisher Policy:Reproduced under a Creative Commons License

University Staff: Request a correction | Enlighten Editors: Update this record